Press Releases

CRANBURY, N.J., Jan. 3, 2013 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN) announced today it has received net proceeds of approximately $1.75 million of non-dilutive funding through the New Jersey Economic Development Authority’s tax credit transfer program.  Palatin Technologies sold both New Jersey net operating losses and research and development tax credits to unrelated corporations. […]

CRANBURY, N.J., Nov. 20, 2012 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN) announced that it will be presenting at the 24th Annual Piper Jaffray Healthcare Conference on Tuesday, November 27, 2012 at 3:10 p.m. Eastern Time.  The conference will be held at The New York Plaza, New York. Carl Spana, Ph.D., President and Chief Executive

CRANBURY, N.J., Nov. 14, 2012 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today announced results for its first quarter ended September 30, 2012.  Recent HighlightsOn July 3, 2012, Palatin closed on a private placement

CRANBURY, N.J., Nov. 12, 2012 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN) announced that it will be presenting at the Lazard Capital Markets 9th Annual Healthcare Conference on Tuesday, November 13, 2012, at 10:30 a.m. Eastern Time.  The conference will be held at The Pierre Hotel, New York City. Carl Spana, Ph.D., President and Chief

CRANBURY, N.J., Nov. 9, 2012 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN) will announce its first quarter, fiscal year 2013 financial results on Wednesday, November 14, 2012 before the open of the U.S. financial markets. Palatin will also conduct a conference call and live audio webcast hosted by its executive management team on November 14, 2012,

CRANBURY, N.J., Nov. 8, 2012 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN) today reported positive top-line results, including the successful achievement of statistical significance for the primary endpoint and key secondary endpoints in its Phase 2B clinical trial evaluating the efficacy and safety of bremelanotide for the treatment of female sexual dysfunction (FSD). The data

CRANBURY, N.J., Sept. 11, 2012 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today announced results for its fourth quarter and fiscal year ended June 30, 2012.  Fiscal Year and Recent Highlights Bremelanotide development for

CRANBURY, N.J., Sept. 10, 2012 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN) today announced that the last patient has completed treatment in its Phase 2B clinical trial evaluating the efficacy and safety of bremelanotide for treatment of female sexual dysfunction (FSD).  Database lock is expected by the end of September and top-line trial results are expected

CRANBURY, N.J., Sept. 7, 2012 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN) today announced that its collaboration partner,  AstraZeneca, has decided to discontinue further development of AZD2820, one of a number of collaboration compounds in various stages of development for the treatment of obesity.  AstraZeneca remains committed to this collaboration program and to the continued

CRANBURY, N.J., Sept.  6, 2012 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN) will announce its fourth quarter, fiscal year 2012 financial results on Tuesday, September 11, 2012 before the open of the U.S. financial markets. Palatin will also conduct a conference call and live audio webcast hosted by its executive management team on September 11,